Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148812 | 0.90 | PTGS2 (0.54) | PTGS2PTGS1NR3C2CYP2C9 | |
| SCHEMBL14504540 | 0.87 | HDAC3 (0.58) | PDPK1PTGS2PTGS1CYP2C9 | |
| SCHEMBL5150503 | 0.87 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL14504539 | 0.87 | PTGS2 (0.60) | PDPK1PTGS2PTGS1CYP2C9 | |
| SCHEMBL5147861 | 0.87 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL5147835 | 0.86 | PTGS2 (0.55) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL5150500 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL5150862 | 0.85 | PTGS2 (0.58) | PTGS2PTGS1CYP2C9 | |
| Hydrochloric Acid SCHEMBL5147821 | 0.84 | PDPK1 (0.54) | MDM2PDPK1PTGS2PTGS1BCL2 | |
| SCHEMBL5150893 | 0.83 | PTGS2 (0.54) | PTGS2PTGS1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | MDM2 1492/4885PDPK1 2205/4885PTGS2 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.